|View printer-friendly version|
|CytomX Highlights Data from Multiple Probody Pipeline Programs at Investor Event During AACR-NCI-EORTC Conference|
Posters containing the data can be found on the Publications page of CytomX's website. A replay of the investor event will be posted on the Investors and News page of CytomX's website at
"Our research team has demonstrated preclinical proof-of-concept for our Probody technology across a number of our pipeline programs. We have consistently shown the ability of the platform to create safer and more effective therapies across multiple antibody modalities in cancer," said
CytomX discussed preclinical results from its lead program CX-072, a PD-L1-directed Probody therapeutic, that were initially presented at the CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference on
Therapeutics developed with CytomX's Probody platform are designed to be active in the tumor while sparing healthy tissue. By restricting activity to the tumor microenvironment, Probody therapeutics directed against both validated and novel targets enable anti-tumor efficacy with a significantly enhanced safety window, relative to traditional antibody-based therapies. CytomX's preclinical pipeline of wholly-owned and partnered programs includes Probody cancer immunotherapies, Probody drug conjugates and T-cell engaging Probody bispecifics.
About CytomX Therapeutics
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cytomx-highlights-data-from-multiple-probody-pipeline-programs-at-investor-event-during-aacr-nci-eortc-conference-300174515.html